Palatin/Mallinckrodt Neutrospec Clears FDA; Imaging Agent Available In Mid-August
This article was originally published in The Pink Sheet Daily
Executive Summary
The radiolabeled monoclonal antibody is approved for diagnosing equivocal appendicitis. Palatin expects to initiate a Phase III trial for diagnosing osteomyelitis by the first quarter of 2005.